TNG260 is a first-in-class, highly selective CoREST complex inhibitor currently being evaluated with pembrolizumab in the dose expansion phase of the TNG260 Phase 1/2 trial. The trial is currently ...

In synthetic and structural biology, advances in artificial intelligence have led to an explosion of designing new proteins ...

AI disruption, led by models like Sora, is accelerating and could displace millions of jobs, pressuring the Fed's dual ...

Rigetti Computing remains a ‘Buy’ despite recent stock volatility and evolving quantum computing trends. Click here to find ...

Sandeep Menon, CEO & Co-Founder at Auxia, brings over two decades of global technology and marketing leadership to the role.

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch ...